

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/720,862	11/24/2003	Timothy J. Taylor	29475/39204	5172
48995	7590 01/24/2006		EXAMINER	
MARSHALL, GERSTEIN & BORUN LLP (DIAL) 233 S. WACKER DRIVE 6300 SEARS TOWER			OGDEN JR, NECHOLUS	
			ART UNIT	PAPER NUMBER
CHICAGO, 1	L 60606		1751	

DATE MAILED: 01/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/720,862	TAYLOR ET AL.				
Office Action Summary	Examiner	Art Unit				
	Necholus Ogden	1751				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 07 No.	<u>ovember 2005</u> .					
2a)⊠ This action is <b>FINAL</b> . 2b)☐ This	This action is <b>FINAL</b> . 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-6 and 9-24</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-6 and 9-24</u> is/are rejected.	6)⊠ Claim(s) <u>1-6 and 9-24</u> is/are rejected.					
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
See the attached detailed Office action for a list of	or the certified copies not receive	a.				
Attachment(s)						
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		atent Application (PTO-152)				

Application/Control Number: 10/720,862

Art Unit: 1751

#### Response to Amendment

Claims 1-6 and 9-24 are pending.

## Claim Rejections - 35 USC § 112

1. Claims 8 and 16 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention are withdrawn in view of applicant's amendment.

### Claim Rejections - 35 USC § 102/35 USC § 103

2. Claims 1-24 rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Beerse et al (6,294,186) is withdrawn in view of applicant's amendment.

# Response to Arguments

- 3. Applicant's arguments with respect to claims 1-6 and 9-24 have been considered but are most in view of the new ground(s) of rejection.
- 4. Claims 1-6 and 9-24 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Wei et al (2002/0098159).

Wei et al disclose an antimicrobial composition comprising a proton donating agent; a surfactant; and wherein the composition has an antibacterial antiviral residual effectiveness index of greater than 1 (col. 2, 0013-0019). Wei et al specifically teach that said compositions are effective against Rhinovirus infections, Staphylococcus aureus; and E. Coli (0008). With respect to compositions of Wei et al, said reference teaches an organic acid in an amount greater than 0.01 and comprises benzoic acid (0033 and 0041); sodium hydroxide to obtain a pH from 2 to 6 (0035-0040); a pKa of

less than 6.0 (0035); and a surfactant in an amount from 0.05% (0045). Wei et al further teach that said compositions comprise 3 to 98.899% by weight of an aqueous components such as ethanol, isopropanol, propylene glycol; or polyethylene glycol (0091-0093). Note, see examples 2-3. With respect to the method claims, Wei et al teach the use of cleansing human skin by applying said composition for 90 seconds and rinsing to kill bacteria or viruses with a log Reduction of greater than 2 (0395).

As this reference teaches all of the instantly required it is considered anticipatory.

In the alternative, the examples do not exemplify applicant's specific benzoic acid, however, it would have been obvious to one of ordinary skill in the art to substitute the pyrrolidone carboxylic acid for the benzoic acid because Wei et al teach the equivalence of benzoic acid and pyrrolidone carboxylic acid, as donating agents and with sufficient specificity, that the skilled artisan would have been motivated to include benzoic acid in the skin cleansing formulation because only equivalent results would have been obtained in view of the teachings disclosed in Wei et al.

### **Double Patenting**

Claims 1-6 and 9-24 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-26 of 6,451,748 is withdrawn in view of applicant's arguments.

With respect to claims 1-15 of U.S. Patent No. and 6,861,397, the examiner maintains the obviousness-type double patenting rejection.

Applicant's argues that the '397 patent recites the presence of about 0.1 to about 15% by weight of a surfactant.

Art Unit: 1751

The examiner contends that applicant's claims require 0 to 0.2% which is an overlap in proportions.

Applicant further argues that '397 patent does not teach or suggest an aromatic carboxylic acid or the claims are silent with respect to an antimicrobial agent.

The examiner contends that the topically active compound recited in claim 1 of the '397 patent refers to salicylic acid (col. 13, line 21), which is applicant's preferred aromatic antimicrobial agent.

#### Conclusion

5. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1751

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Necholus Ogden whose telephone number is 571-272-1322. The examiner can normally be reached on M-Th.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yogendra N. Gupta can be reached on 571-272-1316. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Nectrolus Ogden Primary Examiner Art Unit 1751

No 1**-1**9-06